w88win优德中文版 Assists Genor Biopharma in a Transaction Worth Over US$ 400 Million
2024.11.28
On August 5, 2024, Genor Biopharma (Stock code: 6998.HK) announced that it had entered into a licensing agreement and a stock purchase agreement with TRC 2004. Genor Biopharma agreed to grant the Licensee an exclusive worldwide license, excluding mainland China, Hong Kong, Macau and Taiwan, to develop, use, manufacture, commercialize and otherwise exploit GB261.
According to the agreement, Genor Biopharma shall receive: (1) a significant equity participation in the Licensee; (2) a double digit million US dollars upfront payment; (3) up to US$443 million in milestone payments; and (4) tiered single to double digits royalty payments on net sales.
GB261 is a novel differentiated CD20 / CD3 bi-specific T-Cell Engager with ultra-low affinity to bind CD3 and has Fc-enabled functions (ADCC and CDC). GB261 had previously completed a Phase Ph1/2 multi-center study of B-NHL (DLBCL and FL) in China and Australia, which demonstrated promising efficacy and a favorable safety profile. GB261 has been shown to significantly reduce cytokine release (CRS).
The transaction structure of this deal was complex and encompassed intellectual property licensing, cross-border investment, the application of foreign laws, and the cross-border transfer of human genetic resource information and personal data. w88win优德中文版’s domestic patent, data, corporate and M&A teams, along with its New York office, worked diligently and efficiently to help the client successfully complete the transaction within a short timeframe, demonstrating w88win优德中文版’s strengths in integrated professional division and collaboration.
This deal was led by partners ZHAO, Hao (Gerry), John Du, andLIU, Jiadi, with partners WANG, Qiang (Josh)andDONG, Xiao (Marissa) respectively handling overseas investment and cross-border data transfer.
